HEPATIC IMPAIRMENT

This study tested how a new drug for fatty liver disease (NNC0194-0499) is processed by the body in people with different levels of liver damage compared to healthy people. A total of 33 participants received a single injection of the drug. The main goal was to see if having live…

This study aimed to understand how a new weight management drug, cagrilintide, is processed by the body. Researchers compared how people with different levels of liver function absorbed and cleared the drug after a single injection. The study also measured how the drug entered th…

This study aimed to understand how a drug called palovarotene is processed by the body in people with moderate or severe liver impairment, compared to people with healthy livers. It involved 31 adult participants who were divided into groups based on their liver function. The mai…

This study examined how a single dose of the weight loss drug AMG 133 is processed in people with different levels of liver impairment compared to those with normal liver function. It involved 36 adults to measure drug levels in the blood and check for safety issues. The goal was…

This early-stage study aimed to understand how a single dose of the experimental drug olpasiran is processed by the body in people with different levels of liver damage. It compared 25 participants with mild, moderate, or severe liver impairment to participants with normal liver …

This study aimed to understand how an experimental drug called MK-8527 is processed by the body in people with mild or moderate liver impairment. Researchers compared the drug's behavior in 18 participants—some with liver problems and some healthy. The goal was to gather safety i…

This early-stage study aimed to understand how a liver condition changes the way the body processes a single dose of an experimental drug called ITF2357. It involved 24 people: 16 with mild or moderate liver impairment and 8 with normal liver function. The main goal was to measur…

This study aimed to understand how a drug called MCI-186 is processed by the body in people with mild or moderate liver problems compared to people with normal liver function. It involved 22 participants who received a single dose of the drug. The goal was to gather safety inform…

This early-stage study tested how a new drug called AZD5004 is processed by people with different levels of liver damage compared to people with healthy livers. Researchers gave a single dose to 33 adults with mild, moderate, or severe liver impairment, plus a matched healthy gro…

This study aimed to understand how a drug called divarasib is processed in people with different levels of liver problems compared to healthy people. It involved 31 participants, some with healthy livers and some with mild, moderate, or severe liver impairment. The main goal was …

This study measured how a single dose of the cancer drug repotrectinib behaves in people with moderate or severe liver impairment compared to healthy people. Researchers enrolled 18 adults to understand if liver problems change how the drug moves through the body. The goal was to…

This study looked at how a new drug called AZD2389 is processed by the body in people with different levels of liver problems compared to people with normal liver function. It involved 35 participants who received a single dose of the drug. The main goal was to understand how liv…

This study tested how a new drug, AZD2693, is processed in people with different levels of liver problems compared to people with normal liver function. It involved 35 people who received a single injection. The main goal was to understand if liver impairment changes how the drug…

This study aimed to understand how a drug for fatty liver disease (NASH) is processed by the body in people with moderate to severe liver damage. Researchers compared 22 participants—some with liver impairment and some healthy—after they received a single dose. The main goal was …

This early-stage study tested how a new drug called golcadomide behaves in people with moderate to severe liver problems compared to healthy volunteers. Researchers gave a single dose to 29 participants to measure drug levels in the blood and check for safety issues. The goal was…

This early-stage study aimed to understand how liver function affects the way the body processes bulevirtide, a medication for hepatitis D. Researchers compared 74 participants—some with healthy livers and some with impaired liver function—to measure drug levels in the blood and …

This early-stage study aimed to understand how a drug called BPN14770 behaves in people with different levels of liver damage. Researchers gave a single dose to 32 people, including healthy volunteers and those with mild, moderate, or severe liver impairment. They measured how mu…

This study looked at how a new prostate cancer drug, opevesostat, is processed by the body in men with moderate liver problems compared to healthy men. Researchers gave a single dose to 16 participants and measured drug levels in their blood over time to understand if liver impai…

This early-stage study aimed to understand how a single dose of the experimental drug fosmanogepix is processed by the body in people with different levels of liver function. It involved 28 adults, some with healthy livers and some with mild to severe liver impairment. The main g…

This early-stage study tested how a single dose of an experimental drug called cenerimod is processed by the body in people with mild or moderate liver impairment, compared to healthy volunteers. The main goal was to understand if liver problems change how the drug moves through …

This small, completed study aimed to understand how liver problems affect how the body processes a drug called evobrutinib. It involved 24 people, some with healthy livers and some with mild or moderate liver impairment. Each participant received a single dose so researchers coul…

This study tested how a new drug called KP-001 is processed by the body in people with different levels of liver problems. Researchers gave a single dose to 24 adults, including healthy volunteers and people with mild to severe liver impairment. The goal was to see if liver probl…

This early-stage study aimed to understand how the body processes a single dose of the experimental drug fazirsiran in people with varying levels of liver damage, compared to people with normal liver function. It involved 34 adults, some with liver scarring (cirrhosis) and some w…